NCH2 Stock Overview
Engages in the engineering, procurement, and construction of electrochemical plants in Germany, Italy, Japan, China, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
thyssenkrupp nucera AG & Co. KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €8.89 |
52 Week High | €23.42 |
52 Week Low | €8.61 |
Beta | 0 |
11 Month Change | -1.99% |
3 Month Change | -26.14% |
1 Year Change | -61.20% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -62.22% |
Recent News & Updates
Shareholder Returns
NCH2 | DE Construction | DE Market | |
---|---|---|---|
7D | -8.1% | -2.5% | -0.5% |
1Y | -61.2% | -6.6% | -0.3% |
Return vs Industry: NCH2 underperformed the German Construction industry which returned -5.7% over the past year.
Return vs Market: NCH2 underperformed the German Market which returned -0% over the past year.
Price Volatility
NCH2 volatility | |
---|---|
NCH2 Average Weekly Movement | 6.1% |
Construction Industry Average Movement | 6.1% |
Market Average Movement | 4.6% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NCH2's share price has been volatile over the past 3 months.
Volatility Over Time: NCH2's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1960 | 855 | Werner Ponikwar | thyssenkrupp-nucera.com |
thyssenkrupp nucera AG & Co. KGaA engages in the engineering, procurement, and construction of electrochemical plants in Germany, Italy, Japan, China, and internationally. The company offers green hydrogen, chlor- alkali, and hydrochloric acid solutions. It serves chemical and steel industries, as well as refineries.
thyssenkrupp nucera AG & Co. KGaA Fundamentals Summary
NCH2 fundamental statistics | |
---|---|
Market cap | €1.12b |
Earnings (TTM) | €6.00m |
Revenue (TTM) | €723.10m |
187.1x
P/E Ratio1.6x
P/S RatioIs NCH2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NCH2 income statement (TTM) | |
---|---|
Revenue | €723.10m |
Cost of Revenue | €636.50m |
Gross Profit | €86.60m |
Other Expenses | €80.60m |
Earnings | €6.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | 0.048 |
Gross Margin | 11.98% |
Net Profit Margin | 0.83% |
Debt/Equity Ratio | 0% |
How did NCH2 perform over the long term?
See historical performance and comparison